Jing Huang1, Zhijun Yang1, Jieqing Zhang1, Kun Gao1, He Wang1, Li Li2. 1. Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Laboratory of Early Prevention and Treatment for Regional High Frequence Tumor Ministry of Education Key Laboratory, Nanning 530021, China. 2. Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Laboratory of Early Prevention and Treatment for Regional High Frequence Tumor Ministry of Education Key Laboratory, Nanning 530021, China; Email: lili@gxmu.edu.cn.
Abstract
OBJECTIVE: To discuss the risk factors and prognosis of gynecologic cancer patients with deep venous thrombosis (DVT). METHODS: Data from gynecologic cancer patients diagnosed by cytology or histopathology in Affiliated Tumor Hospital of Guangxi Medical University between Jan. 1994 and Sep. 2014 were collected, including 106 cases in the DVT group, according to 1:1 proportion by the computer random method to selecting patients without DVT as the control group. The follow-up deadline was March 31, 2015. The median follow-up time of DVT group was 27.0 months (range, 1 to 169 months), while the control group was 33.5 months (range, 1 to 125 months). Univariate analysis was performed by two independent sample t test or χ² test. Multivariate analysis was performed by logistic regression analysis. The Kaplan-Meier curve was used to estimate the survival analysis. RESULTS: (1) The univariate analysis showed that body mass index (BMI), hypertension, diabetes, history of thrombosis, tumor stage, blood transfusion, stimulating factor, white blood cell (WBC), platelet (PLT), prothrombin time (PT) and fibrinogen (FIB) were statistically significant associated with DVT (P < 0.05). Multivariate analysis showed that tumor stage, stimulating factor, WBC, PT and FIB may be the independent risk factors of gynecologic cancer with DVT (P < 0.05). (2) The median survival time in DVT group was 66 months, while the control group was 102 months (χ² = 7.039, P = 0.008). The overall survival and progression-free survival in the DVT group were statistically significant lower than those in the control group (P < 0.05). The tumor stage, the scope of DVT (whether with pulmonary embolism) and the treatment of DVT were the effective factors influenced the prognosis of gynecologic oncology patients with DVT (P < 0.05). Cox regression model showed that tumor stage and the scope of DVT were the independent risk factors (P < 0.01). CONCLUSIONS: Gynecologic cancer with DVT is the common effect of various risk factors. We should identify the risk factors for high-risk patients and take preventive measures actively to reduce the deep venous thromboembolism, then improve the survival of patients and their prognosis.
OBJECTIVE: To discuss the risk factors and prognosis of gynecologic cancerpatients with deep venous thrombosis (DVT). METHODS: Data from gynecologic cancerpatients diagnosed by cytology or histopathology in Affiliated Tumor Hospital of Guangxi Medical University between Jan. 1994 and Sep. 2014 were collected, including 106 cases in the DVT group, according to 1:1 proportion by the computer random method to selecting patients without DVT as the control group. The follow-up deadline was March 31, 2015. The median follow-up time of DVT group was 27.0 months (range, 1 to 169 months), while the control group was 33.5 months (range, 1 to 125 months). Univariate analysis was performed by two independent sample t test or χ² test. Multivariate analysis was performed by logistic regression analysis. The Kaplan-Meier curve was used to estimate the survival analysis. RESULTS: (1) The univariate analysis showed that body mass index (BMI), hypertension, diabetes, history of thrombosis, tumor stage, blood transfusion, stimulating factor, white blood cell (WBC), platelet (PLT), prothrombin time (PT) and fibrinogen (FIB) were statistically significant associated with DVT (P < 0.05). Multivariate analysis showed that tumor stage, stimulating factor, WBC, PT and FIB may be the independent risk factors of gynecologic cancer with DVT (P < 0.05). (2) The median survival time in DVT group was 66 months, while the control group was 102 months (χ² = 7.039, P = 0.008). The overall survival and progression-free survival in the DVT group were statistically significant lower than those in the control group (P < 0.05). The tumor stage, the scope of DVT (whether with pulmonary embolism) and the treatment of DVT were the effective factors influenced the prognosis of gynecologic oncology patients with DVT (P < 0.05). Cox regression model showed that tumor stage and the scope of DVT were the independent risk factors (P < 0.01). CONCLUSIONS: Gynecologic cancer with DVT is the common effect of various risk factors. We should identify the risk factors for high-risk patients and take preventive measures actively to reduce the deep venous thromboembolism, then improve the survival of patients and their prognosis.